source
- GSK’s B7-H4 ADC shows 62% response in platinum-resistant ovarian cancer, PFS 11 monthsGSK’s global head of oncology R&D presented new early-stage data on its B7-H4‑directed antibody‑drug conjugate, mo‑rez, at the ESMO conference in Madrid. The update focused on the ongoing Behold‑1…
- AbbVie’s lutikizumab meets primary endpoint in phase 3 hidradenitis suppurativa trial but falls short of competitive benchmarksAbbVie reported that its experimental antibody lutikizumab achieved the primary endpoint in the phase 3 Intrepid study for hidradenitis suppurativa. The trial enrolled about 1,400 patients and at…